AgBiotech Company Cibus Poised for Strong Growth

Cibus

In June 2023, Cibus, a U.S.-based agricultural biotech company, successfully concluded its merger with Calyxt, another AgBiotech company. This merger brings together two companies with a focus on agriculture-based gene editing for trait development and next-generation plant breeding. Now operating under the combined name Cibus (NASDAQ: CBUS), the merged company is poised for significant growth in revenue projections, based on Visible Alpha consensus estimates.

Following the merger, analysts expect the company to see its revenue grow from an estimated $1.1 million in 2023 to $105 million by 2027, growing at a CAGR of 211%. According to Visible Alpha consensus, the company’s EBITDA is expected to turn positive by 2027, generating a projected EBITDA margin of 7%.

Sector: Materials
Industry: Fertilizers & Agricultural Chemicals
VA Ticker(s): CBUS_US